Volume 1.40 | Oct 22

Prostate Cell News 1.40, October 22, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Vitamin E in Front Line of Prostate Cancer Fight 
Survival rates of the world’s most common cancer might soon be increased with a new vitamin E treatment which could significantly reduce tumour regrowth. A team of researchers have identified a particular constituent of vitamin E, tocotrienol (T3), which can inhibit the growth of prostate tumours. [Press release from Queensland University of Technology discussing online prepublication in the International Journal of Cancer]

RoboSep_645x110_v02



SPECIAL FEATURE

Interested in recruiting talented individuals? Post your career opportunities in Prostate Cell News at no cost. Contact us at info@connexoncreative.com



SCIENCE NEWS

Prostate Cancer Patients are at Increased Risk of Precancerous Colon Polyps
Men with prostate cancer should be especially diligent about having routine screening colonoscopies, results of a new study indicate. [Press release from the University at Buffalo discussing data presented at the American College of Gastroenterology meeting in San Antonio, Texas]

Mount Sinai Researchers Find Potential Therapeutic Target Across a Range of Cancer Types
Researchers have found a common link among several malignant tumor types in all grades of cancer. [Press release from EurekAlert! discussing online prepublication in The New England Journal of Medicine]

Watch Procedure Now  
Detect 7x More Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies
 
 
CLICK HERE TO LEARN HOW STEMCELL Technologies Inc
 



CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

A New Paradigm for Aptamer Therapeutic AS1411 Action: Uptake by Macropinocytosis and Its Stimulation by a Nucleolin-Dependent Mechanism
AS1411 is a first-in-class anticancer agent, currently in phase II clinical trials. It is a quadruplex-forming oligodeoxynucleotide that binds to nucleolin as an aptamer, but its mechanism of action is not completely understood. Here, researchers compare uptake of fluorophore-labeled AS1411 (FL-AS1411) in DU145 prostate cancer cells (sensitive to AS1411) and Hs27 nonmalignant skin fibroblasts (resistant to AS1411). [Cancer Res]

Cediranib/AZD2171 Inhibits Bone and Brain Metastasis in a Preclinical Model of Advanced Prostate Cancer
Researchers describe here the effects of cediranib, a receptor tyrosine kinase inhibitor, in a model of advanced prostate cancer metastatic to skeleton and brain. [Cancer Res]

FTY720 (Fingolimod) Sensitizes Prostate Cancer Cells to Radiotherapy by Inhibition of Sphingosine Kinase-1
A sphingosine analogue, FTY720 (fingolimod), a drug currently in phase III studies for treatment of multiple sclerosis, has been found to be a potent apoptosis inducer in prostate cancer cells. Using in vitro and in vivo approaches, researchers analyzed the impact of FTY720 on sphingolipid metabolism in hormone-refractory metastatic prostate cancer cells and evaluated its potential as a radiosensitizer on cell lines and prostate tumor xenografts. [Cancer Res]

Regulation of the Androgen Receptor by SET9-Mediated Methylation
Here, researchers show that the androgen receptor interacts with and is directly methylated by the histone methyltransferase enzyme SET9. [Nucleic Acids Res]

NAMPT Overexpression in Prostate Cancer and its Contribution to Tumor Cell Survival and Stress Response
In this study, researchers show that nicotinamide phosphoribosyltransferase (NAMPT) is prominently overexpressed in human prostate cancer cells along with SIRT1. [Oncogene]

The Bcl-2-Beclin 1 Interaction in (-)-Gossypol-Induced Autophagy Versus Apoptosis in Prostate Cancer Cells
The results provide new insights into the mode of cell death induced by Bcl-2 inhibitors, which could facilitate the rational design of clinical trials by selecting patients who are most likely to benefit from the Bcl-2-targeted molecular therapy. [Autophagy]

Procyanidin B3, an Inhibitor of Histone Acetyltransferase, Enhances the Action of Antagonist for Prostate Cancer Cells via Inhibition of p300-Dependent Acetylation of Androgen Receptor
Increasing evidence suggests that androgen receptor acetylation is critical for prostate cancer cell growth. In this study, researchers identified procyanidin B3 as a specific histone acetyltransferase inhibitor. [Biochem J]

Gamma-Tocotrienol as an Effective Agent in Targeting Prostate Cancer Stem Cell-Like Population
Here, researchers demonstrate for the first time that gamma-tocotrienols (gamma-T3) can downregulate the expression of prostate cancer stem cell markers (CD133/CD44) in androgen-independent prostate cancer cell lines (PC-3 and DU145), as evident from Western blotting analysis. [Int J Cancer]

CLINICAL RESEARCH

Expression of Follicle-Stimulating Hormone Receptor in Tumor Blood Vessels
Follicle-stimulating hormone receptor is selectively expressed on the surface of the blood vessels of a wide range of tumors. [N Engl J Med]

Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population
In this study, researchers analyze the association of single-nucleotide polymorphisms in p53, Mdm2, Mdm4, and Hausp genes with prostate cancer clinicopathologic variables in a large hospital-based Caucasian prostate cancer cohort (N = 4,073). [Clin Cancer Res]

Detection of Xenotropic Murine Leukemia Virus-Related Virus in Normal and Tumor Tissue of Patients from the Southern United States with Prostate Cancer Is Dependent on Specific Polymerase Chain Reaction Conditions
Xenotropic Murine Leukemia Virus (XMRV) is detectable in normal and tumor prostate tissue from patients with prostate cancer, independent of R462Q (RNASEL R462Q polymorphism). The presence of XMRV in normal tissue suggests that infection may precede cancer onset. [J Infect Dis]



INDUSTRY NEWS

Molecular Insight Pharmaceuticals Data Indicate Trofex(TM) May Enable Visualization and Monitoring of Response to Prostate Cancer Treatment
Molecular Insight Pharmaceuticals, Inc. presented data from a preclinical study that indicate Trofex™ (123I-MIP-1072), its lead molecular imaging candidate for the detection of metastatic prostate cancer, may also be used to visualize changes in tumor volume in response to treatment of the disease. [Molecular Insight Pharmaceuticals, Inc. Press Release]

Agensys, an Affiliate of Astellas, and Seattle Genetics Announce Initiation of Phase I Clinical Trial of ASG-5ME for Prostate Cancer
Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of castration-resistant prostate cancer. [Seattle Genetics, Inc. Press Release]



POLICY NEWS

FDA: Include Warnings on Risk for Class of Prostate Cancer Drugs
The U.S. Food and Drug Administration today asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer. [Food and Drug Administration, United States]

European Medicines Agency Strengthens Rules on Conflicts of Interests of Its Scientific Experts
The European Medicines Agency has published new rules on how the Agency will be handling potential conflicts of interests of its scientific experts, following endorsement by its Management Board. [European Medicines Agency, European Union]

IQWiG: Law Must Prescribe Obligation to Publish All Clinical Trials
If the currently discussed draft on the “Law on the Reorganization of the Pharmaceutical Market” (AMNOG) is implemented, drug manufacturers will in future have to register their clinical trials at inception and publish results after completion. [Institute for Quality and Efficiency in Health Care (IQWiG), Germany]

Loss of UK Genetics Public Bodies Confirmed
The official announcement from the UK Government on the future of non-departmental public bodies has confirmed the rumored abolition of a total of 192 public bodies, with a further 118 to be merged. [Foundation for Genomics and Population Health, United Kingdom]

HHS to Let Secretary’s Genetics Committee Expire  The Secretary’s Advisory Committee on Genetics, Health, and Society will disband next month, eight years after its founding. The committee had completed its original task, advising the Department of Health and Human Services (HHS) on a number of issues related to genomics. [Department of Health and Human Services, United States]

Screening Framework Guidance for Providers of Synthetic Double-Stranded DNA (FR Doc. 2010-25728) [Department of Health and Human Services, United States]

Proposed Collection; Comment Request; National Evaluation of the Clinical and Translational Science Awards (CTSA) Initiative (FR Doc. 2010-25589) [Department of Health and Human Services, United States]

Agency Information Collection Request. 30-Day Public Comment Request (FR Doc. 2010-25587) [Department of Health and Human Services, United States]

Partnerships To Advance the National Occupational Research Agenda (NORA) (FR Doc. 2010-25973) [Centers for Disease Control and Prevention, United States]

Office of the Director, National Institutes of Health; Notice of Meeting (FR Doc. 2010-26036) [National Institutes of Health, United States]

National Human Genome Research Institute; Notice of Closed Meeting (FR Doc. 2010-25634) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-25595) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-25597) [National Institutes of Health, United States]

Center for Scientific Review; Amended Notice of Meeting (FR Doc. 2010-25598) [National Institutes of Health, United States]

Center for Scientific Review; Amended Notice of Meeting (FR Doc. 2010-25601) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26028) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26033) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-25636) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-25640) [National Institutes of Health, United States]

National Cancer Institute; Notice of Meeting (FR Doc. 2010-26032) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meetings (FR Doc. 2010-26035) [National Institutes of Health, United States]

National Institute of General Medical Sciences; Notice of Closed Meeting (FR Doc. 2010-26037) [National Institutes of Health, United States]

National Institute of General Medical Sciences; Notice of Closed Meeting (FR Doc. 2010-26075) [National Institutes of Health, United States]



EVENTS (Listed by Date)

Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain

Select Biosciences 3rd Annual Molecular Diagnostics World Congress
October 28-29, 2010
San Diego, United States

United Arab Emirates (UAE) Cancer Congress 2010
October 28-30, 2010
Dubai, United Arab Emirates

Queen Mary, University of London: 5th UK Cancer Stem Cell Symposium
November 2, 2010
London, United Kingdom

National Cancer Research Institute (NCRI) Conference 2010
November 7-10, 2010
Liverpool, United Kingdom

9th Annual American Association for Cancer Research (AACR): International Conference: Frontiers in Cancer Prevention Research
November 7-10, 2010
Philadelphia, United States

22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium: Molecular Targets and Cancer Therapeutics
November 16-19, 2010
Berlin, Germany

Cancer Pharmacogenetics: Personalizing Medicine
November 22-24, 2010
Madrid, Spain

American Association for Cancer Research (AACR): Tumor Immunology – Basic and Clinical Advances
November 30-December 3, 2010
Miami, United States

5th Annual Stem Cell Meeting on the Mesa
December 7, 2010
La Jolla, United States

11th Annual Meeting of the Society of Urologic Oncology (SUO): Extraordinary Opportunities for Discovery
December 8-9, 2010
Bethesda, United States

American Association for Cancer Research (AACR): Targeting PI3K/mTOR Signaling in Cancer
February 24-27, 2011
San Francisco, United States

American Association for Cancer Research (AACR): Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

MENA Oncology Conference
March 11-12, 2011
Cairo, Egypt

The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics
March 16-19, 2011
Las Vegas, United States

American Association for Cancer Research (AACR): 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

National Cancer Institute (NCI) Cancer Research Imaging Camp
June 19-24, 2011
St. Louis, United States

4th Annual Advances in Biodetection & Biosensors Conference and Exhibition
June 30-July 1, 2011
Hamburg, Germany

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES


Clean Room Team Leader – Cellular Therapy (Cell Medica Limited)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News at no cost.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.


Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us